Pasithea Therapeutics Stock News

Pasithea Therapeutics Corp (KTTA) shares closed today 36.7% higher than it did at the end of yesterday. The stock is currently down 43.5% year-to-date, down 43.5% over the past 12 months, and down 43.5% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $2.38 and as low as $1.39 this week.Shares closed 76.4% below its 52-week high and 44.6% above its 52-week low.Trading volume this week was 85.4% lower than the 10-day average and 71.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company.

Pasithea Therapeutics Corp (NASDAQ: KTTA ) is trading higher on abnormally-high volume Thursday. Pasithea Therapeutics'' average session volume is about 2.6 million over a 100-day period, according to data from Benzinga Pro . Thursday''s trading volume has already exceeded 75 million at publication time. When asked about Thursday''s price action, Pasithea Therapeutics CEO Tiago Reis Marques told Benzinga that Full story available on Benzinga.com

Can these three penny stocks continue to make gains next month? The post Top Penny Stocks to Watch During Today's Bull Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto

Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company. The post KTTA Stock Alert: 6 Things to Know About Pasithea Therape

 Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom -- Expanding Pasithea Clinics footprint in London -- Miami Beach, FL -- December 21st, 2021 -- InvestorsHub NewsWire -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its wholly owned subsidiary, Pasithea Clinics, has opened i...

Pasithea Therapeutics Corp (KTTA) shares closed 0.7% lower than its previous 52 week low, giving the company a market cap of $19M. The stock is currently down 58.4% year-to-date, down 58.4% over the past 12 months, and down 58.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 2.0%. Trading Activity Trading volume this week was 42.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Pasithea Therapeutics Corp. (KTTA) with the stream of -16.42% also noticed, India AgeX Therapeutics, Inc. (AGE) encountered a rapid change of -3.42% in the last hour of trading session. Pasithea The post Beholding Stock: Pasithea Therapeutics Corp. (NASDAQ:KTTA), AgeX Therapeutics, Inc. (AMEX:AGE) appeared first on Stocks Equity .

      Pasithea Therapeutics  Expands its Mobile Clinics into Florida and Nevada   -- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals -- -- Expansion to additional U.S. cities in coming months --   Miami Beach, FL / December 1, 2021 -- InvestorsHub NewsWire -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or...

-- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals --

MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (Pasithea or the Company), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the closing of its previously announced private placement of common stock and warrants priced at a premium to the market under Nasdaq rules. The Company sold an aggregate of 8.68 million shares of common stock and warrants to purchase 8.68 million shares of common stock at a purchase price of $3.50 per share and accompanying warrant for gross proceeds to the Company of $30.4 million, before deducting the placement agent''s fees and other estimated offering expenses.

Pasithea Therapeutics Corp. (NASDAQ:KTTA) traded at $4.01 at close of the session on Friday, 11/26/21, made an upward move of 0.50% on its previous days price. Looking at the stock we see that its previous close was $3.99 with the days price range being $3.80 $4.39. In terms of its 52-week price range, KTTA Investors Take Advantage Of 0.50% Gain In Pasithea Therapeutics Corp. (NASDAQ: KTTA) Read More »

Pasithea Therapeutics Corp (KTTA) shares closed this week 66.3% higher than it did at the end of last week. The stock is currently up 12.1% year-to-date, up 12.1% over the past 12 months, and up 12.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $8.50 and as low as $2.10 this week.Trading volume this week was 28.9% lower than the 10-day average and 134.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Pasithea Therapeutics Corp (NASDAQ: KTTA ) shares shed their gains from yesterday after it announced a private offering of 8.68 million shares and warrants to purchase 8.68 million shares. The offer price of $3.50 per share represents a steep discount of 38% from the last close price of $5.60 that more Full story available on Benzinga.com